Search results
Added:
6 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
ESC 24: MRAs in HF
Added:
1 year ago
Video
Added:
10 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more
Added:
1 year ago
ESC Congress — Ms Carys Barton (Imperial College Healthcare NHS Trust, London, UK) joins us on-site to talk about the implementation of heart failure guidelines.Interview Questions:1. What are the biggest challenges in implementing heart failure guidelines?2. How do nurses help implement guidelines, and what strategies do they use?3. What training can help with guideline implementation?4. How can…
View more
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more
Added:
8 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and…
View more
Added:
1 week ago
HFA Congress 2026 — SUBCUT-HF II: subcutaneous furosemide for early supported discharge in worsening heart failure. Dr Ross Campbell (University of Glasgow, UK) shares results from SUBCUT-HF II, a multicentre, phase 2, randomised controlled trial evaluating subcutaneous furosemide in patients hospitalised with worsening heart failure.A total of 172 patients across 22 UK centres were randomised to…
View more
Added:
1 year ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different…
View more
Added:
1 week ago
HFA Congress 2026 - Dr Kevin Damman (University Medical Centre Groningen, Groningen, NL) joins us to discuss findings from a study-level meta-analysis combining data from the DECISION, DIGIT-HF and DIG trials to evaluate the role of digitalis glycosides (digoxin and digitoxin) in heart failure with reduced and mildly reduced ejection fraction.This analysis brings together evidence from three…
View more